Loading…
Based on limited metadata, Nutra Pharma received an FDA Warning Letter on March 11, 2019, regarding drug products. Without access to the full letter text or detailed subject information, the specific nature of the violations cannot be determined from the available metadata alone. The warning falls under FDA's drug regulatory authority, though the specific issuing office is not identified in the metadata provided. Additional documentation would be needed to detail the particular compliance issues cited.